Shopping Cart
- Remove All
- Your shopping cart is currently empty
Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $169 | In Stock | |
5 mg | $448 | In Stock | |
10 mg | $715 | In Stock | |
25 mg | $1,080 | In Stock | |
50 mg | $1,460 | In Stock |
Description | Pacmilimab (CX-072) is a Probody immune checkpoint inhibitor targeting programmed death ligand 1 (PD-L1) with anti-tumor activity for the study of solid tumors. |
In vivo | Pacmilimab demonstrated anti-tumor effects in MC38 tumor model mice that matched the effects of the parental antibody at the same dose. [1] Pacmilimab predominantly clustered in tumor tissues of PD-L1-expressing mice, with minimal uptake in peripheral non-tumorigenic lymphoid tissues. This distributional property suggests that its uptake in non-tumorigenic PD-L1-expressing tissues is limited and may contribute to the maintenance of immune self-tolerance. [1] |
Alias | CX-072, CX072 |
Cas No. | 2145091-51-4 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.